DIPROSALIC OINTMENT

Ülke: Kanada

Dil: İngilizce

Kaynak: Health Canada

Aktif bileşen:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE); SALICYLIC ACID

Mevcut itibaren:

ORGANON CANADA INC.

ATC kodu:

D07XC01

INN (International Adı):

BETAMETHASONE

Doz:

0.5MG; 30MG

Farmasötik formu:

OINTMENT

Kompozisyon:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.5MG; SALICYLIC ACID 30MG

Uygulama yolu:

TOPICAL

Paketteki üniteler:

15G/50G

Reçete türü:

Prescription

Terapötik alanı:

ANTI-INFLAMMATORY AGENTS

Ürün özeti:

Active ingredient group (AIG) number: 0215695004; AHFS:

Yetkilendirme durumu:

APPROVED

Yetkilendirme tarihi:

2021-04-16

Ürün özellikleri

_DIPROSALIC_
_®_
_ Lotion and Ointment (Betamethasone Dipropionate and Salicylic Acid)
_
_ _
_Page 1 of 15_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
DIPROSALIC
®
Betamethasone Dipropionate and Salicylic Acid Lotion
Betamethasone Dipropionate and Salicylic Acid Ointment
Betamethasone 0.5 mg/g (as Betamethasone Dipropionate) and Salicylic
Acid 20 mg/g
Betamethasone 0.5 mg/g (as Betamethasone Dipropionate) and Salicylic
Acid 30 mg/g
60 mL topical lotion
50 g topical ointment
Topical Corticosteroid and Keratolytic
ORGANON CANADA INC.
16766 route Transcanadienne
Kirkland, Quebec
H9H 4M7
www.organon.ca
Date of Initial Approval:
October 04, 1982
Date of Revision:
April 15, 2021
Submission Control No.: 249786
_ _
_DIPROSALIC_
_®_
_ Lotion and Ointment (Betamethasone Dipropionate and Salicylic Acid)
_
_ _
_Page 2 of 15_
TABLE OF CONTENTS
TABLE OF CONTENTS ..............................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION ............................................................3
1
INDICATIONS
....................................................................................................................3
1.1
Pediatrics
....................................................................................................................3
1.2
Geriatrics
....................................................................................................................3
2
CONTRAINDICATIONS ..................................................................................................3
3
DOSAGE AND ADMINISTRATION ...............................................................................3
3.1
Dosing Considerations
...............................................................................................3
3.2
Recommended Dose and Dosage Adjustment
...........................................................3
4
MISSED DOSE ......................................................................................